SPOTLIGHT -
EP. 1: Treatment for High-Risk Asymptomatic Myeloma
EP. 2: Emerging Regimens for Smoldering Myeloma
EP. 3: Induction Therapy for Myeloma
EP. 4: Initial Therapy for High-Risk Myeloma
EP. 5: Transplant-Eligible Multiple Myeloma
EP. 6: MRD as a Composite End Point in Myeloma
EP. 7: Outcomes With Transplant in Myeloma
EP. 8: CD38-Targeted Monoclonal Antibodies in Myeloma
EP. 9: Choosing Front-Line Therapy for Myeloma
EP. 10: Nuances of Using Frontline Daratumumab for Myeloma
EP. 11: Considering Daratumumab-Based Quadruplets for Myeloma
EP. 12: Maintenance Therapy for Multiple Myeloma
EP. 13: Outcomes for Relapsed/Refractory Myeloma
EP. 14: Treatment Options for Lenalidomide-Refractory Myeloma
EP. 15: Coming Soon: Isatuximab + Pom/Dex for Relapsed Myeloma
EP. 16: BCMA-Targeted Approaches for Relapsed Myeloma
EP. 17: Real-World Use of BCMA-Targeted Therapy in Myeloma
Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC
Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases
Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC
Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC
